Literature DB >> 25218893

Epilepsy in Menkes disease: an electroclinical long-term study of 28 patients.

Alberto Verrotti1, Raffaella Cusmai2, Francesca Darra3, Paola Martelli4, Patrizia Accorsi4, Silvia Bergamo5, Elsa Bevivino2, Giangennaro Coppola6, Elena Freri7, Salvatore Grosso8, Sara Matricardi7, Pasquale Parisi9, Stefano Sartori5, Alberto Spalice10, Nicola Specchio2, Alessia Carelli11, Daniela Zini3, Bernardo Dalla Bernardina3, Lucio Giordano4.   

Abstract

BACKGROUND: Epilepsy is a frequent and severe feature of Menkes disease (MD) but only few studies described the long-term evolution of these children. We report a series of 28 epileptic MD patients, with clinical characteristics, EEG abnormalities, brain malformations and long-term outcome.
METHODS: EEG, clinical characteristics and neuroimaging features in 28 MD patients were analyzed at the onset of epilepsy and after long-term follow-up (at least 4 years). We subdivided the patients into two groups: Group 1, 16 patients who received a subcutaneous copper-histidine treatment, and Group 2 including 12 patients who did not get any therapies.
RESULTS: The large majority of our patients presented at the onset of epilepsy focal seizures (FS) and infantile spasms (IS). Five patients had recurrent status epilepticus (SE). During the follow-up, patients showed multiple seizure types: 6 patients had generalized tonic clonic seizures (GCT), 6 patients presented IS, 10 children had FS, 11 had myoclonic jerks and 3 had SE. Therapy with various antiepileptic drugs had poor efficacy, except in three patients who showed seizure disappearance with consequent discontinuation of antiepileptic therapy. There was no difference of neurological outcome among the two groups analyzed.
CONCLUSIONS: Epilepsy in MD is a difficult to treat problem. At the onset, the most frequent type of seizures are FC and IS; in the next months, other kinds of seizures can appear. Many children are drug resistant. Institution of replacement therapy with copper-histidine seems to be not beneficial for epilepsy.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  EEG; Epilepsy; Menkes disease; Status epilepticus

Mesh:

Substances:

Year:  2014        PMID: 25218893     DOI: 10.1016/j.eplepsyres.2014.08.006

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  4 in total

1.  Identification of novel ATP7A mutations and prenatal diagnosis in Chinese patients with Menkes disease.

Authors:  Binbin Cao; Xiaoping Yang; Yinyin Chen; Qionghui Huang; Ye Wu; Qiang Gu; Jiangxi Xiao; Huixia Yang; Hong Pan; Junya Chen; Yu Sun; Li Ren; Chengfeng Zhao; Yanhua Deng; Yanling Yang; Xingzhi Chang; Zhixian Yang; Yuehua Zhang; Zhengping Niu; Juli Wang; Xiru Wu; Jingmin Wang; Yuwu Jiang
Journal:  Metab Brain Dis       Date:  2017-04-10       Impact factor: 3.584

Review 2.  Metabolic etiologies in West syndrome.

Authors:  Seda Salar; Solomon L Moshé; Aristea S Galanopoulou
Journal:  Epilepsia Open       Date:  2018-03-14

3.  Early clinical signs and treatment of Menkes disease.

Authors:  Chie Fujisawa; Hiroko Kodama; Yasuhiro Sato; Masakazu Mimaki; Mariko Yagi; Hiroyuki Awano; Muneaki Matsuo; Haruo Shintaku; Sayaka Yoshida; Masaki Takayanagi; Mitsuru Kubota; Akihito Takahashi; Yoshikiyo Akasaka
Journal:  Mol Genet Metab Rep       Date:  2022-02-17

Review 4.  Mottled Mice and Non-Mammalian Models of Menkes Disease.

Authors:  Małgorzata Lenartowicz; Wojciech Krzeptowski; Paweł Lipiński; Paweł Grzmil; Rafał Starzyński; Olga Pierzchała; Lisbeth Birk Møller
Journal:  Front Mol Neurosci       Date:  2015-12-18       Impact factor: 5.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.